Edition:
United Kingdom

Neuralstem Inc (CUR.OQ)

CUR.OQ on NASDAQ Stock Exchange Capital Market

0.52USD
24 Apr 2019
Change (% chg)

$-0.03 (-5.11%)
Prev Close
$0.55
Open
$0.54
Day's High
$0.55
Day's Low
$0.48
Volume
45,392
Avg. Vol
40,119
52-wk High
$1.84
52-wk Low
$0.26

Latest Key Developments (Source: Significant Developments)

Neuralstem Appoints Ken Carter As Executive Chairman Of The Board
Tuesday, 18 Dec 2018 

Dec 18 (Reuters) - Neuralstem Inc ::NEURALSTEM APPOINTS KEN CARTER, PH.D., AS EXECUTIVE CHAIRMAN OF THE BOARD.KENNETH C. CARTER, PH.D., AS CO'S EXECUTIVE CHAIRMAN OF BOARD TO BE EFFECTIVE ON JANUARY 1, 2019.CARTER WILL REPLACE INTERIM CEO, JIM SCULLY, WHO WILL BE STEPPING DOWN.  Full Article

Neuralstem Q3 Loss Per Share $0.12
Wednesday, 14 Nov 2018 

Neuralstem Inc ::NEURALSTEM REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q3 LOSS PER SHARE $0.12.  Full Article

Neuralstem Appoints Jim Scully As Interim CEO
Monday, 6 Aug 2018 

Aug 6 (Reuters) - Neuralstem Inc ::NEURALSTEM APPOINTS JIM SCULLY AS INTERIM CHIEF EXECUTIVE OFFICER.NEURALSTEM - SCULLY WILL SUCCEEDS RICH DALY WHO SERVED AS PRESIDENT AND CEO OF COMPANY SINCE FEBRUARY 2016.  Full Article

Neuralstem says NSI-566 Stem Cell Therapy Confers Neurological Improvement In Spinal Cord Injury
Monday, 4 Jun 2018 

June 4 (Reuters) - Neuralstem Inc ::NEURALSTEM’S NSI-566 STEM CELL THERAPY CONFERS NEUROLOGICAL IMPROVEMENT IN SPINAL CORD INJURY PATIENTS WITH COMPLETE PARAPLEGIA.NEURALSTEM INC - ANALYSIS OF MOTOR AND SENSORY FUNCTION AND ELECTROPHYSIOLOGY RESULTS SHOWED IMPROVEMENT IN THREE OF FOUR PATIENTS.NEURALSTEM INC - ALL SUBJECTS TOLERATED PROCEDURE WELL, WITH NO SERIOUS ADVERSE EVENTS 18-27 MONTHS AFTER GRAFTING.  Full Article

Neuralstem Says At Dec. 31, 2017, Cash And Investments Was $11.7 Mln Compared To $20.2 Mln At Dec. 31, 2016
Monday, 2 Apr 2018 

April 2 (Reuters) - Neuralstem Inc ::NEURALSTEM REPORTS YEAR END 2017 FISCAL RESULTS AND BUSINESS UPDATE.AT DECEMBER 31, 2017, CASH AND INVESTMENTS WAS $11.7 MILLION AS COMPARED TO $20.2 MILLION AT DECEMBER 31, 2016.TERM INVESTMENTS TO FUND OPERATIONS INTO Q2 OF 2019.  Full Article

Neuralstem Q3 loss per share $0.01
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Neuralstem Inc :Neuralstem reports third quarter 2017 fiscal results and provides clinical and business update.Q3 loss per share $0.01.Neuralstem - ‍expect to provide detailed update on corporate strategy after post-phase 2 meeting with fda in h1 2018​.Neuralstem Inc - ‍ recent financing further extended co's cash runway to sufficiently support continued research on NSI-189 and to support operations​.Neuralstem Inc - ‍plans to meet with U.S. Food and Drug Administration in first half of 2018 to discuss clinical development path for NSI-189​.  Full Article

Neuralstem Inc gets two additional U.S. patents
Thursday, 7 Sep 2017 

Sept 7 (Reuters) - Neuralstem Inc :Neuralstem Inc - ‍been awarded two additional patents by United States Patent and Trademark Office​.  Full Article

Neuralstem reports Q2 loss per share $0.39
Tuesday, 8 Aug 2017 

Aug 8 (Reuters) - Neuralstem Inc :Neuralstem reports second quarter 2017 fiscal results and provides clinical and business update.Q2 loss per share $0.39.  Full Article

‍CVI investments reports a 8.3 pct passive stake in Neuralstem
Monday, 7 Aug 2017 

Aug 7 (Reuters) - Neuralstem Inc :‍CVI Investments reports a 8.3 percent passive stake in Neuralstem Inc as of July 27, 2017 - SEC filing.  Full Article

Neuralstem announces top-line phase 2 data of nsi-189 for major depressive disorder
Tuesday, 25 Jul 2017 

July 25 (Reuters) - Neuralstem Inc ::Neuralstem announces top-line phase 2 data of nsi-189 for major depressive disorder.Neuralstem Inc - ‍study did not meet its primary efficacy endpoint​.Neuralstem Inc - 40 mg qd dose was directionally positive on madrs​.Both 40 mg QD and 40 MG bid doses of NSI-189 were well-tolerated in study with no serious adverse events reported.Neuralstem Inc - ‍results were also directionally positive on hamilton depression rating scale (ham-d17) at both doses​.Neuralstem - ‍of two secondary efficacy endpoints analyzed so far, patient-rated SDQ achieved statistical significance with NSI-189 40 MG QD​.  Full Article